Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with No Late Stent Thrombosis or Additional Major Adverse Cardiac Events Out to Three Years

BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE), and no late stent thrombosis in patients treated with either Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION(R) metallic coronary stent. Additionally, data presented from a meta- (combined) analysis of SPIRIT II and SPIRIT III trials at nine months reaffirmed the superiority of Abbott's XIENCE V compared to the TAXUS(R) paclitaxel-eluting coronary stent system in a variety of measures.

These data were presented today at the EuroPCR meeting in Barcelona.

"The SPIRIT FIRST results support the long-term safety of the XIENCE V system, with no additional MACE or late stent thrombosis, by both protocol and ARC definitions, out to three years," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, and an investigator in the SPIRIT trials. "In addition, a meta-analysis of the SPIRIT II and III data again demonstrated the superiority of the XIENCE V system to the TAXUS system in important measures that matter to patients including renarrowing of a treated vessel and major adverse cardiac events."

A meta-analysis of approximately 1,300 patients from the SPIRIT II and SPIRIT III clinical trials conducted by the Cardiovascular Research Foundation indicated that the XIENCE V system demonstrated superiority over the TAXUS stent in angiographic (imaging) and clinical endpoints, with an excellent safety profile.

Specifically, data from the meta-analysis demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System was superior to the TAXUS stent in:

    -- Reducing the occurrence of major 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)...  Bluestar Silicones will promote its Silbione® Biomedical ... implant applications and announce certification of its clean ... West Conference (Booth #1759), February 9-10, at the ... --> Available in 01 through 70 ... physical properties enabling our customers to optimize their ...
(Date:2/8/2016)... -- Alzheimer Diagnostic Tests - Medical Devices Pipeline ... sector report , "Alzheimer Diagnostic Tests - Medical ... Alzheimer Diagnostic Tests currently in pipeline stage. ... products with comparative analysis of the products at ... players involved in the pipeline product development. It ...
(Date:2/8/2016)... Devices - Medical Devices Pipeline Assessment, 2015 Summary ... Medical Devices Pipeline Assessment, 2015" provides an overview of ... This report is prepared using data sourced from in-house ... industry experts. *Note: Certain sections in the report ... and relevance of data in relation to the equipment ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South Youth ... Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening session ... FHU and the creator of GO! Camp, has been named director. Gayle McDonald, currently ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross ... Specialists are delighted to welcome a new addition to their growing practice. Beginning ... Specialists as a nurse practitioner performing cosmetic procedures including injectables, fillers ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... concussion, yet the cause of injury may be one of many possible sources: ... PT Continuing Education Course , Mastering Rehab Solutions for the Complexities ...
(Date:2/9/2016)... , ... February 09, 2016 , ... Steven Douglas Associates ... of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s ... guests alike. This year the event will be held in a new, more causal ...
(Date:2/9/2016)... ... 09, 2016 , ... Interstate Restoration LLC, a full service ... the acquisition of Hawaii DKI. Hawaii DKI is one of the more recognized ... who excel at service and response helps support our goal of becoming the ...
Breaking Medicine News(10 mins):